- Citations, last 5 years
- 11
- Works, last 5 years
- 3
- h-index
- 17
- Scientists listed
- 0
- Grants since 2016
- 19
Grants received
2019 · research · R44
Mutant transgenic plant cells as a novel source of drugs
John M. Littleton · Naprogenix (United States) · funded by National Institutes of Health
2018–2020 · research · R43
Mimicking synuclein toxicity in plant cells to identify novel neuroprotective leads
John M. Littleton · Naprogenix (United States) · funded by National Institutes of Health
2018–2023 · research · R44
Mimicking synuclein toxicity in plant cells to identify novel neuroprotective leads
John M. Littleton · Naprogenix (United States) · funded by National Institutes of Health
2018–2025 · research · R44
Mimicking synuclein toxicity in plant cells to identify novel neuroprotective leads
Chifu Huang · Naprogenix (United States) · funded by National Institutes of Health
2018–2023 · research · R44
Mimicking synuclein toxicity in plant cells to identify novel neuroprotective leads
John M. Littleton · Naprogenix (United States) · funded by National Institutes of Health
2017–2025 · cooperative agreement · U44
Development of JR-220 (4-Chlorobenzylidenamino-guanidine hydrochloride) as a medication for alcohol dependence
Cindy Ann Burklow · Naprogenix (United States) · funded by National Institutes of Health
2017–2024 · cooperative agreement · U44
Development of JR-220 (4-Chlorobenzylidenamino-guanidine hydrochloride) as a medication for alcohol dependence
John M. Littleton · Naprogenix (United States) · funded by National Institutes of Health
2017–2025 · cooperative agreement · U44
Development of JR-220 (4-Chlorobenzylidenamino-guanidine hydrochloride) as a medication for alcohol dependence
Cindy Ann Burklow · Naprogenix (United States) · funded by National Institutes of Health
2017–2022 · cooperative agreement · U44
Development of JR-220 (4-Chlorobenzylidenamino-guanidine hydrochloride) as a medication for alcohol dependence
John M. Littleton · Naprogenix (United States) · funded by National Institutes of Health
2017–2021 · cooperative agreement · U44
Development of JR-220 (4-Chlorobenzylidenamino-guanidine hydrochloride) as a medication for alcohol dependence
John M. Littleton · Naprogenix (United States) · funded by National Institutes of Health
2017–2024 · cooperative agreement · U44
Development of JR-220 (4-Chlorobenzylidenamino-guanidine hydrochloride) as a medication for alcohol dependence
Cindy Ann Burklow · Naprogenix (United States) · funded by National Institutes of Health
2016–2023 · research · R44
Novel modulators of the dopamine transporter for alcohol and nicotine use disorders
John M. Littleton · Naprogenix (United States) · funded by National Institutes of Health
2016–2023 · research · R44
Novel modulators of the dopamine transporter for alcohol and nicotine use disorders
John M. Littleton · Naprogenix (United States) · funded by National Institutes of Health
2016–2026 · research · R44
Novel modulators of the dopamine transporter for alcohol and nicotine use disorders
Cindy Ann Burklow · Naprogenix (United States) · funded by National Institutes of Health
2016–2017 · contract · N44
IGF::OT::IGF POTENTIAL COMMERCIALIZATION OF PROPRIETARY COMPOUND JR-220
John Littleton · Naprogenix (United States) · funded by National Institutes of Health
2016–2019 · research · R44
Mutant transgenic plant cells as a novel source of drugs
John M. Littleton · Naprogenix (United States) · funded by National Institutes of Health
2016–2023 · research · R44
Novel modulators of the dopamine transporter for alcohol and nicotine use disorders
John M. Littleton · Naprogenix (United States) · funded by National Institutes of Health
2016–2018 · research · R44
Mutant transgenic plant cells as a novel source of drugs
John M. Littleton · Naprogenix (United States) · funded by National Institutes of Health
2014–2020 · research · R44
Harvesting specific plant metabolites from hairy root cultures using magnetized nanoparticles
John M. Littleton · Naprogenix (United States) · funded by National Institutes of Health